Benzinga | Aug 16, 2021 04:30PM EDT

INVO Bioscience Q2 Net Loss ~$1.8M, Adj. EBITDA Loss $1.3M, Sales $208.47K Miss $410.00K Estimate

INVO Bioscience (NASDAQ:INVO) reported quarterly sales of $208.47 thousand which missed the analyst consensus estimate of $410.00 thousand by 49.15 percent.